利妥昔单抗用于东非EBV阳性伯基特淋巴瘤患儿
在东非开展的前瞻性非随机观察性研究中,年龄≤25岁确诊伯基特淋巴瘤患者分别接受INCTR标准化疗(COM)或利妥昔单抗联合标准化疗(R-COM)。中位随访23个月,R-COM组12个月无事件生存率67%,COM组43%(HR 0.49;95%CI 0.24-0.98;P=0.045);R-COM组死亡8例,COM组死亡16例(HR 0.32;95%CI 0.14-0.75;P=0.009)。
要点
- 在经验丰富的东非中心,R-COM方案被观察到安全可行并能挽救生命。
- 12个月无事件生存率R-COM组67% vs COM组43%(HR 0.49;95%CI 0.24-0.98;P=0.045)。
- R-COM组死亡8例 vs COM组死亡16例(HR 0.32;95%CI 0.14-0.75;P=0.009)。
核心结论
- 在经验丰富的东非中心,EBV阳性伯基特淋巴瘤患者接受INCTR方案(COM)联合利妥昔单抗被观察到安全可行并能挽救生命。
研究设计与样本
- 前瞻性非随机观察性研究,纳入东非年龄≤25岁确诊伯基特淋巴瘤患者,接受COM或R-COM方案,主要终点为安全性,次要终点为无事件生存、总生存及利妥昔单抗的成本效益,主要分析基于意向治疗人群。
- 安全性分析纳入72例患者:COM组32例,R-COM组40例;中位随访23个月。
主要发现
- ≥3级不良事件发生率R-COM组18% vs COM组16%。
- 12个月时,R-COM组观察到5例事件,COM组14例事件。
- 12个月无事件生存率R-COM组67% vs COM组43%(HR 0.49;95%CI 0.24-0.98;P=0.045)。
- R-COM组死亡8例 vs COM组死亡16例(HR 0.32;95%CI 0.14-0.75;P=0.009)。
- R-COM在晚期疾病中特别有效。
临床怎么用
- 原文未据此给出推荐,仅报告在经验丰富的东非中心观察到R-COM方案安全可行并能挽救生命。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The addition of rituximab to the chemotherapy backbone was shown to significantly improve outcomes of children with aggressive high-grade lymphomas in high-income countries. However, data on its safety and efficacy in children with Epstein-Barr virus (EBV)-positive Burkitt lymphoma (BL) are limited. We conducted a prospective nonrandomized observational study in East African patients aged ≤25 years with confirmed BL. Patients received either the International Network for Cancer Treatment and Research (INCTR)-based standard chemotherapy (cyclophosphamide, vincristine, and methotrexate [COM]) or rituximab plus standard chemotherapy (R-COM). The primary end point was safety. The secondary outcomes were event-free and overall survival and cost-effectiveness of incorporating rituximab. Primary analyses were conducted in the intention-to-treat population. The median follow-up was 23 months. Safety analyses included 72 patients: 32 in the COM group and 40 in the R-COM group. Grade ≥3 adverse events occurred in 18% of R-COM patients and 16% of COM patients. With respect to treatment outcomes at 12 months, 5 events were observed in the R-COM group and 14 in the COM group. The 12-month event-free survival was 67% with R-COM and 43% with COM (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.24-0.98; P = .045). There were 8 deaths in the R-COM group, whereas 16 patients died in the COM group (HR, 0.32; 95% CI, 0.14-0.75; P = .009). R-COM was particularly effective in advanced-stage disease. The addition of rituximab to the INCTR-based protocol (COM) for EBV-positive BL has been observed to be safe and feasible in experienced centers in East Africa and saves lives.
引用
- Mawalla WF, Achola C, Nabalende H, et al. Rituximab for children with EBV-positive Burkitt lymphoma in East Africa. Blood Adv. 2025. PMID: 39983056. doi:10.1182/bloodadvances.2024015234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。